Although PD-L1 immunohistochemistry testing in tumor samples is recommended by international guidelines [15], it has several limitations, including variability in results with different immunohistochemistry clones and the requirement for enough tissue material [15], among others. The gene discussed is CD274; the disease is neoplasm.